Peipei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peipei Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Arthur Mark Richards
Cardiovascular Research Institute, National University Health System, Singapore 117599, Singapore
1 shared publication - Azizah Binti Fadzil
Cardiovascular Research Institute, National University Health System, Singapore 117599, Singapore
1 shared publication - Christopher John Charles
Christchurch Heart Institute, Department of Medicine, University of Otago, Christchurch 8014, New Zealand
1 shared publication - Lee Lee Wong
Cardiovascular Research Institute, National University Health System, Singapore 117599, Singapore
1 shared publication - Miriam T. Rademaker
Christchurch Heart Institute, Department of Medicine, University of Otago-Christchurch, Christchurch, New Zealand
1 shared publication - Qiying Chen
Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 6 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 16015
Interrogating the Role of miR-125b and Its 3′isomiRs in Protection against Hypoxia
MiR-125b has therapeutic potential in the amelioration of myocardial ischemic injury. MicroRNA isomiRs, with either 5′ or 3′ addition or deletion of nucleotide(s), have been reported from next-generation sequencing data (NGS). However, due to technical challenges, validation and functional studies of isomiRs are few. In this study, we discovered using NGS, four 3′isomiRs of miR-125b, i.e., addition of A (adenosine), along with deletions of A, AG (guanosine) and AGU (uridine) from rat and sheep heart. These findings were validated using RT-qPCR. Comprehensive functional studies were carried out in the H9C2 hypoxia model. After miR-125b, isomiRs of Plus A, Trim A, AG and AGU mimic transfection, the H9C2 cells were subjected to hypoxic challenge. As assessed using cell viability, apoptosis, CCK-8 and LDH release, miR-125b and isomiRs were all protective against hypoxia. However, Plus A and Trim A were more effective than miR-125b, whilst Trim AG and Trim AGU had far weaker effects than miR-125b. Interestingly, both the gene regulation profile and apoptotic gene validation indicated a major overlap among miR-125b, Plus A and Trim A, whilst Trims AG and AGU revealed a different profile compared to miR-125b. Conclusions: miR-125b and its 3′ isomiRs are expressed stably in the heart. miR-125b and isomiRs with addition or deletion of A might function concurrently and concordantly under specific physiological and pathophysiological conditions. In-depth understanding of isomiRs’ metabolism and function will contribute to better miRNA therapeutic drug design.
- 6 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (21) , 16015
Open AccessInterrogating the Role of miR-125b and Its 3′isomiRs in Protection against Hypoxia
MiR-125b has therapeutic potential in the amelioration of myocardial ischemic injury. MicroRNA isomiRs, with either 5′ or 3′ addition or deletion of nucleotide(s), have been reported from next-generation sequencing data (NGS). However, due to technical challenges, validation and functional studies of isomiRs are few. In this study, we discovered using NGS, four 3′isomiRs of miR-125b, i.e., addition of A (adenosine), along with deletions of A, AG (guanosine) and AGU (uridine) from rat and sheep heart. These findings were validated using RT-qPCR. Comprehensive functional studies were carried out in the H9C2 hypoxia model. After miR-125b, isomiRs of Plus A, Trim A, AG and AGU mimic transfection, the H9C2 cells were subjected to hypoxic challenge. As assessed using cell viability, apoptosis, CCK-8 and LDH release, miR-125b and isomiRs were all protective against hypoxia. However, Plus A and Trim A were more effective than miR-125b, whilst Trim AG and Trim AGU had far weaker effects than miR-125b. Interestingly, both the gene regulation profile and apoptotic gene validation indicated a major overlap among miR-125b, Plus A and Trim A, whilst Trims AG and AGU revealed a different profile compared to miR-125b. Conclusions: miR-125b and its 3′ isomiRs are expressed stably in the heart. miR-125b and isomiRs with addition or deletion of A might function concurrently and concordantly under specific physiological and pathophysiological conditions. In-depth understanding of isomiRs’ metabolism and function will contribute to better miRNA therapeutic drug design.